Separate and Combined Effects of the GABA Reuptake Inhibitor Tiagabine and Δ9-THC in Humans Discriminating Δ9-THC

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2011 Oct 7

PMID 21975195

Citations 12

Authors

Joshua A Lile

Thomas H Kelly

Lon R Hays

Affiliations

Soon will be listed here.

Abstract

Background: The involvement of non-cannabinoid neurotransmitter systems in the abuse-related behavioral effects of cannabis has not been well characterized in humans. GABAergic drugs have overlapping effects with cannabis and Δ(9)-tetrahydrocannabinol (Δ(9)-THC) on certain behavioral measures, but those measures lack the specificity to draw conclusions regarding the involvement of GABA in cannabinoid effects. The aim of this study was to assess the separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ(9)-THC using more pharmacologically specific drug-discrimination procedures.

Methods: Eight cannabis users learned to discriminate 30 mg oral Δ(9)-THC from placebo and then received tiagabine (6 and 12 mg), Δ(9)-THC (5, 15 and 30 mg) and placebo, alone and in combination. Self-report, task performance and physiological measures were also collected.

Results: Δ(9)-THC produced subjective effects typically associated with cannabinoids (e.g., High, Stoned, Like Drug), elevated heart rate and impaired rate and accuracy on psychomotor performance tasks. The higher tiagabine dose substituted for the Δ(9)-THC discriminative stimulus and engendered subjective and performance-impairing effects that overlapped with those of Δ(9)-THC when administered alone. In combination, tiagabine shifted the discriminative-stimulus effects of Δ(9)-THC leftward/upward and enhanced Δ(9)-THC effects on other outcomes.

Conclusions: These results indicate that GABA is involved in the clinical effects of Δ(9)-THC, and by extension, cannabis. Future studies should test selective GABAergic compounds to determine which receptor subtype(s) are responsible for the effects observed when combined with cannabinoids.

Citing Articles

Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action.

Alayoubi M, Henry B, Cahill C, Cooper Z Drugs. 2024; 84(11):1395-1417.

PMID: 39388076 PMC: 11602823. DOI: 10.1007/s40265-024-02098-1.

The neuroprotective effect of traditional Chinese medicinal plants-A critical review.

Moreira J, Machado M, Dias-Teixeira M, Ferraz R, Delerue-Matos C, Grosso C Acta Pharm Sin B. 2023; 13(8):3208-3237.

PMID: 37655317 PMC: 10465969. DOI: 10.1016/j.apsb.2023.06.009.

Combining noninvasive brain stimulation with behavioral pharmacology methods to study mechanisms of substance use disorder.

Wesley M, Lile J Front Neurosci. 2023; 17:1150109.

PMID: 37554294 PMC: 10405288. DOI: 10.3389/fnins.2023.1150109.

The Influence of Recreational Substance Use in TMS Research.

Turco C, Arsalan S, Nelson A Brain Sci. 2020; 10(10).

PMID: 33080965 PMC: 7603156. DOI: 10.3390/brainsci10100751.

Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.

Wesley M, Westgate P, Stoops W, Kelly T, Hays L, Lile J Exp Clin Psychopharmacol. 2018; 26(3):310-319.

PMID: 29863387 PMC: 5990026. DOI: 10.1037/pha0000180.

References

Lile J, Kelly T, Pinsky D, Hays L . Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. Psychopharmacology (Berl). 2008; 203(2):241-50. PMC: 2712322. DOI: 10.1007/s00213-008-1393-3. View

Heishman S, Stitzer M, Yingling J . Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav. 1989; 34(1):173-9. DOI: 10.1016/0091-3057(89)90369-9. View

Kastberg H, Jansen J, Cole G, Wesnes K . Tiagabine: absence of kinetic or dynamic interactions with ethanol. Drug Metabol Drug Interact. 2000; 14(4):259-73. DOI: 10.1515/dmdi.1998.14.4.259. View

Haney M, Hart C, Vosburg S, Nasser J, Bennett A, Zubaran C . Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2003; 29(1):158-70. DOI: 10.1038/sj.npp.1300310. View

Hart C, Haney M, Vosburg S, Comer S, Foltin R . Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl). 2005; 181(2):237-43. DOI: 10.1007/s00213-005-2234-2. View

Moreira F, Wotjak C . Cannabinoids and anxiety. Curr Top Behav Neurosci. 2011; 2:429-50. DOI: 10.1007/7854_2009_16. View

Matsuda L, Lolait S, Brownstein M, Young A, Bonner T . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284):561-4. DOI: 10.1038/346561a0. View

Hohmann A, Herkenham M . Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse. 2000; 37(1):71-80. DOI: 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K. View

Hall W, Lynskey M . Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 2005; 24(1):39-48. DOI: 10.1080/09595230500126698. View

10.

Lile J, Kelly T, Hays L . Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC. Drug Alcohol Depend. 2011; 116(1-3):86-92. PMC: 3089804. DOI: 10.1016/j.drugalcdep.2010.11.019. View

11.

Hashimotodani Y, Ohno-Shosaku T, Kano M . Endocannabinoids and synaptic function in the CNS. Neuroscientist. 2007; 13(2):127-37. DOI: 10.1177/1073858406296716. View

12.

Hohmann A . Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 2002; 121(1-2):173-90. DOI: 10.1016/s0009-3084(02)00154-8. View

13.

Bestard J, Toth C . An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2010; 11(4):353-68. DOI: 10.1111/j.1533-2500.2010.00427.x. View

14.

Frosini M, Valoti M, Sgaragli G . Changes in rectal temperature and ECoG spectral power of sensorimotor cortex elicited in conscious rabbits by i.c.v. injection of GABA, GABA(A) and GABA(B) agonists and antagonists. Br J Pharmacol. 2003; 141(1):152-62. PMC: 1574176. DOI: 10.1038/sj.bjp.0705593. View

15.

Coull M, Johnston A, Pertwee R, Davies S . Action of delta-9-tetrahydrocannabinol on GABA(A) receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice. Neuropharmacology. 1998; 36(10):1387-92. DOI: 10.1016/s0028-3908(97)00110-x. View

16.

Rosenberg G . The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell Mol Life Sci. 2007; 64(16):2090-103. PMC: 11149473. DOI: 10.1007/s00018-007-7079-x. View

17.

Romero J, De Miguel R, Ramos J, Fernandez-Ruiz J . The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci. 1998; 62(4):351-63. DOI: 10.1016/s0024-3205(97)01117-x. View

18.

Romero J, Seale G, Fernandez-Ruiz J, Walker J . Activational role of cannabinoids on movement. Eur J Pharmacol. 2000; 391(3):269-74. DOI: 10.1016/s0014-2999(00)00044-3. View

19.

Antonelli T, Tomasini M, Mazza R, Fuxe K, Gaetani S, Cuomo V . Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety. J Pharmacol Exp Ther. 2009; 329(2):708-17. DOI: 10.1124/jpet.109.150649. View

20.

Holtzman S, Locke K . Neural mechanisms of drug stimuli: experimental approaches. Psychopharmacol Ser. 1988; 4:138-53. View